NCT05116189 · OUTCOME

Overall Survival (OS)

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). · Source last updated 2026-03-09

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to ~64 months

What was measured

OS is defined as the time from the date of randomization to death due to any cause. The OS will be reported for all participants.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: OS is defined as the time from the date of randomization to death due to any cause. The OS will be reported for all participants.
reporting Status: NOT_POSTED
time Frame: Up to ~64 months
title: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice